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INTRODUCTION
Stroke is lack of blood supplement to an
area of the brain, resulting in a loss of
neurological function.1 This disease is the
third leading cause of death worldwide after
cardiovascular disease and cancer.2, 3 Ischemia
is the decreased blood supplement to an
organ or a part of the body which reduces
the transport of oxygen and nutrients into
tissues and as a result causes dysfunction of
the organs. Ischemia may be caused by
atherosclerosis, blood clotting, vasoconstriction,
embolism, low blood pressure and some
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ABSTRACT
Background and aims: Ischemic stroke is the most common type of stroke and its most
important symptoms are paralysis and movement disorders. Therefore, finding a method
for treating this disorder is greatly important. This study was conducted to investigate the
clinical efficacy of frankincense on the patients with ischemic stroke.
Methods: In this clinical trial study, 60 patients with ischemic stroke were randomly
assigned into two groups of treatment and control (30 patients in each group). In the
treatment group, in addition to the routine treatment of stroke, four capsules containing 500
mg of powdered frankincense were used daily, but in the control group, only the treatment
of stroke (without frankincense) was implemented. Treatment continued for one month.
NIHSS questionnaire (to assess speech and muscle strength) was completed at the baseline,
on the seventh day and at the end of treatment for each patient. In this study, statistical
analysis was carried out by t- test, chi-square and Mann-Whitney using SPSS software.
Results: The results showed that only in the second step in the treatment group, the rate of
recovery of the left lower and muscle strength of upper limbs was significantly increased in
patients compared to the control group.
Conclusion: Introducing frankincense into treatment for stroke patients can contribute in
improving muscle strength of the patients with muscle weakness in non-dominant
hemisphere in acute phase of neurological disorder, while it has no effect improvement of
muscle strength of right limbs or speech.
Keywords: Stroke, Frankincense, Movement disorder, Speech disorder.
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cancers.4 One type of ischemia is ischemic
stroke,5 which includes three sub-groups,
thrombosis, embolism and reduced systemic
perfusion, the most common problems of the
blood supplement to the brain and other
organs.6
Stroke has many symptoms, the most
marked of which are hemiparesis and
hemiplegia (weakness and/or paralysis of
one half of the body).2, 3 In this disease, by
neurologic examination, the disorder is
recognized and then confirmed by CT scan
or MRI.7-9 For the treatment of the disease in
acute phase, various drugs such as
antiplatelet agents, anticoagulants and blood
pressure-lowering drugs are used, and
antidepressants are given in the chronic
phase.10 Olibnum (frankincense) is a resin
made from a plant belonging to the
Burseraceae family and the genus of
Boswellia,11,12 which contains many
compounds 13,14 including boswellic acids as
the most abundant.15 Frankincense important
derivatives include β-boswellic acid, 3-
acetyl-β-boswellic acid, 11-keto-boswellic
acid and 3-acetyl-11-keto-β-boswellic
acid.16
According to the conducted studies,
terpenoid acids particularly β-boswellic acid
and its derivations act as anti-inflammatory
agents and specific inhibitors of the enzyme
5-lipoxygenase (the enzyme responsible for
inflammation).17 Another compound found
in this resin is incensole acetate which may
also have a neuroprotective state, anti-
depression and anti-anxiety effects, with
anti-inflammatory effects on the brain.18,19
Frankincense, in Islamic and Iranian
traditional medicine, has been recommended
to enhance memory in the elderly and also to
promote intelligence in the children, so
pregnant women have been advised to
consume it.20,21 Also, many studies have
been done to demonstrate these activities. In
a study, the effect of daily consumption of
one ml of frankincense aqueous extract
(containing 20 mg oral frankincense) on
significant increase in the power of learning
in post learning stage, short-term memory
and long term memory was reported in
neonatal rats in treatment group.22
In another study, frankincense effect on
memory loss was investigated in the mice
with hypothyroidism. The researchers found
that the use of frankincense could prevent
learning disorder and memory loss caused
by hypothyroidism.23 It should be noted that
based on the toxicology studies of
frankincense resin on animals, significant
pathological, hematologic and genotoxic
changes were not caused at up to 1000
mg/kg concentrations.24 In addition, the side
effects are insignificant and negligible in
humans, and only in some cases nausea,
reflux and digestive disorders have been
reported, but on the interaction with other
drugs, no report has been yet published.25
The growing prevalence of stroke and
central nervous system vascular disorders in
today communities, and its debilitating
clinical symptoms and severe and
irreversible complications such as paralysis
greatly affected the patient's daily and
routine activities. On the other hand,
stupendous economic costs are needed for
treating these complications by
physiotherapy and occupational therapy. In
this study, for the first time, the therapeutic
effects of frankincense were examined
accompanied with anticoagulant and
anti-platelet drugs on recovery of muscle
strength and speech ability in patients with
ischemic stroke.
METHODS
This is a single-blinded clinical trial
study conducted on 60 patients referred to
Emergency of Ayatollah Kashani Hospital
of Shahrekord with stroke symptoms and CT
scan diagnosis of ischemic stroke in this
hospital within six months. Sampling was
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done per non-probability, convenience
method. Therefore, the patients with all
inclusion criteria (sudden onset of symptoms
and diagnosis of ischemic stroke) were
enrolled into the study after consent was
obtained, and then they were assigned
randomly into two groups, treatment
(receiving capsules containing powdered
frankincense) and control (without
frankincense administration).
The two groups were matched for age,
gender, clinical symptoms and place of
ischemia in CT scan. Then, in the treatment
group routine treatment of stroke alongside
frankincense capsule (one 500 mg
frankincense capsules taken every 6 hours),
and in the control group, routine treatment
of stroke without frankincense capsule were
implemented. The patients with gradual
onset of symptoms and non-ischemic stroke
were excluded from the study.
It should be noted that frankincense is used
routinely for many years and is part of the
therapeutic regimen for stroke patients, and
hence causes no pharmacologic intervention in
these patients. It is also used in traditional
medicine in most countries and it has been
accepted by people. In this study, after giving
sufficient explanation to patients, written
consent was obtained from them and the study
protocol was approved by the Ethics Committee
of Shahrekord University of Medical Sciences.
All patients underwent treatment for one
month and then NIHSS questionnaire (a
quantitative instrument to measure
neurological disorder of stroke),26 only the
sections concerning movement and speech,
was administered, so that two questions were
related to limbs’ muscle strength with
maximum score 4 (the lowest strength) and
minimum score 0 (the highest strength) for
each question, and two questions were related
to speech with maximum score 3 (the lowest
ability) and minimum score 0 (the highest
ability) for each question. At the end, the
scores were aggregated and analyzed.
The assigned practitioner and physician
had the questionnaires filled out in three
steps, before treatment, the first week after
treatment (in hospital) and at the end of a
month. The third step of filling out the
questionnaires was run after arrangement
with the patients, so that the patients who
were able to refer the clinic were followed
up while they were present in person and
those who were not were followed up by
telephone.
Then, the data were analyzed by SPSS
software 17 using independent t- test, chi-
square and Mann-Whitney in SPSS
software.
RESULTS
In the treatment group, of 30 patients
with a mean age of 71.5 ± 12.1 years, 14
(46.7%) patients were men and 16 (53.3%)
were women, and of 30 patients in the
control group with a mean age of 73.9 ± 8.4
years, 12 (40%) patients were men and 18
(60%) were women. Using t-test showed no
significant difference in age and gender
between two groups (P=0.37 and 0.60,
respectively).
The range and median of muscle
weakness in patients of the two groups are
summarized in Table 1. By Mann-Whitney
test, in the first step (before treatment), for
the type of neurological disorder, 17
(28.3%) had muscle weakness in the right
limbs, 21 (35%) had muscle weakness in the
left limbs and 22 (36.7%) had speech
disorder. No significant difference was seen
in neurological disorder between two groups
(P>0.05). In the second step (first week after
treatment), the rate of recovery of left limbs
was significantly higher in the treatment
group than the control group (P=0.036). No
significant difference was seen in recovery
rate of right limbs between two groups
(P=0.481). No significant difference was
seen in speech disorder treatment between
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two groups (P=0.847), as well. In the third
step (after one month of treatment), no
significant difference was seen in the rate of
limbs and speech recovery between two
groups (P>0.05). Frequency distribution of
CT scan results is shown in Table 2. By chi-
square, frequency distribution of CT scan
was similar in two groups (P=0.544).
Table 1: Range and median of neurological disorder in two groups, treatment and control
Type of
involvement
Step Control Treatment P-value
Minimum Maximum Median Minimum Maximum Median
Right hand First 1 4 2 1 4 3 0.88
Second 0 3 1 0 3 0.5 0.42
Third 0 3 1 0 3 0.5 0.81
Left hand First 1 4 3 1 4 2 0.13
Second 0 3 2 0 3 1 0.72
Third 0 3 1 0 3 1 0.11
Right leg First 1 4 2 1 4 3 0.88
Second 0 3 1 0 3 0.5 0.48
Third 0 2 1 0 3 0.5 0.96
Left leg First 1 4 3 1 4 2 0.13
Second 0 3 1.5 0 2 1 0.29
Third 0 3 1 0 3 1 0.173
Right leg First 2 6 2 2 6 2 0.84
Second 0 6 2 0 2 2 0.84
Third 0 6 1 0 2 2 1
Left hand and
leg
First 2 8 6 2 8 4 0.13
Second 0 6 3.5 0 4 2 0.03
Third 0 6 2 0 6 2 0.11
Right hand
and leg
First 2 8 4 2 8 6 0.88
Second 0 6 2 0 6 1 0.48
Third 0 5 2 0 6 1 0.88
Table 2: Frequency distribution of CT scan result in patients of treatment and control groups
NormalRight ischemiaLeft ischemiaCT scan
Groups %No.%No.%No.
36.711401223.37Control
43.31326.78309Treatment
By chi-square test, there was no significant difference in frequency distribution of CT
scan between the two groups (P>0.05).
DISCUSSION
The results of the present study
indicated that use of frankincense capsules
accompanied with treatment alone could
significantly increase the rate of recovery of
disorder in the left limbs in the second step
(acute phase).
In several studies, the effect of frankincense
on nervous system has been investigated.
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Moussaieff et al. studied the neuroprotective
effects of incensole acetate (one of
frankincense derivatives) on rats with head
trauma and investigated cognitive function
and neurological behavior of rats, and
reported that this resin had anti-
inflammatory activity and most probably
neuroprotective effects.18 Hosseini
Sharifabad et al. reported that, after daily
use of frankincense extract (100 mg/kg) in
lactating rats, the cell body volume of
neurons in the hippocampus (an index to
improve the performance of the
hippocampus) of infants increased.27 These
researchers also examined the effect of
aqueous extract of frankincense during
lactation on the morphology of neurons in
the hippocampus of rats’ infants, and
reported an increase in hippocampal
dendritic branches.28
Also, some researchers investigated
anti-inflammatory and blood cholesterol-
lowering effects of frankincense. In a study
of acetyl-11-keto-β-boswellic acid effect
(one of frankincense derivatives and natural
inhibitor of proinflammatory transcription
factor nuclear factor kB (NFkB) on
atherosclerotic plaques in mice with
deficiency of ApoE, it was reported that the
frankincense, through inhibition of NFkB
activity, can be used as a traditional
medicine for the treatment of chronic
inflammatory diseases such as
atherosclerosis.29 Dashti et al. investigated
the effect of frankincense extract (500
mg/kg) on the atherosclerosis in the
coronary arteries of rabbits fed with a high
cholesterol diet after five weeks, and
reported that frankincense, through
influencing lipid metabolism, can reduce
serum cholesterol levels, triglycerides and
lipoprotein, and reduce atherosclerosis in all
vessels.30 Most of these studies confirm the
present study findings. However, most
studies have studied mice and only one
study has examined the effect of
frankincense on the human nervous system.
Kirste et al. in study of frankincense effect
on brain edema in patients undergoing
radiotherapy for brain tumors reported that
brain edema was significantly reduced in the
group receiving frankincense.31 It seems that
since one of the pathophysiologies of stroke
is the brain edema due to ischemia,
frankincense can also be effective on the
patients’ symptoms, which was partially
confirmed by the present study. However,
frankincense was demonstrated to contribute
in treatment of movement disorder in acute
phase in the patients’ left limbs in the
present study, which could be explained by
possibly greater frankincense effect in the
patients with impaired non-dominant
hemisphere, and the use of some drugs such
as neuroaid capsule at the third step by both
groups of treatment and control could
explain recovery of the symptoms in the two
groups at this step.
CONCLUSION
In view of the results of the present
study, introducing frankincense into
treatment for stroke patients can contribute
to improving muscle strength of the patients
with muscle weakness in non-dominant
hemisphere in acute phase of neurological
disorder, while it has no effect on
improvement of muscle strength of right
limbs or speech. Of course, it is better to
investigate frankincense effect on other
symptoms in the patients with stroke and
chronic ischemic stroke, and also more
research should be conducted to further
elucidate frankincense effect on the
mechanism of cerebral ischemia.
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